Literature DB >> 12717064

Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.

M Karam1, A Gianoukakis, P J Feustel, A Cheema, E S Postal, J A Cooper.   

Abstract

Radioiodine ablation of thyroid tissue after subtotal thyroidectomy has been shown to decrease recurrence in certain subsets of patients with well-differentiated thyroid cancer. In a substantial percentage of cases (20-30%), initial ablation of the thyroid remnant fails, necessitating a second treatment. The factors associated with ablation failure are not fully understood. In particular, it is not certain whether the use of doses higher than 3.70 GBq would result in any additional benefit, or whether there is a 'stunning' effect of the diagnostic dose of 131I on the subsequent ablation rate. A retrospective analysis was performed of all patients (n=389) with well-differentiated thyroid cancer treated at our institution between 1992 and 2001. Remnant ablation success was determined by a whole-body radioiodine scan. The following factors, thought to be associated with thyroid remnant ablation, were studied by logistic regression analysis: age, gender, tumour histology, stage, pre-therapy neck uptake of 131I, diagnostic dose, ablation dose, time between diagnostic and therapeutic dose (T1), time between therapeutic administration and the first follow-up whole-body scan (T2) and the thyroid-stimulating hormone (TSH) level measured at the time of therapy. Follow-up whole-body scans were available in 214 patients. We found no association with age, gender, histology, TSH level, neck uptake, diagnostic dose and successful ablation. The therapeutic dose was the only variable found to be associated with success (odds ratio, 1.96 per 1.85 GBq increment; 95% confidence interval, 1.11-3.46). Our results confirm the presence of a significant percentage of ablation failures (24.4%) despite the use of high ablative doses (3.70-7.40 GBq). Higher therapeutic doses are associated with higher rates of successful ablation, even when administered to patients with more advanced stages. Using our protocol, higher diagnostic doses were not associated with higher rates of ablation failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12717064     DOI: 10.1097/00006231-200305000-00002

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  10 in total

1.  Radioiodine Scan Index: A Simplified, Quantitative Treatment Response Parameter for Metastatic Thyroid Carcinoma.

Authors:  Jong-Ryool Oh; Byeong-Cheol Ahn; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2015-04-28

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

3.  Development and application of a novel sensitive immunometric assay for calcitonin in a large cohort of patients with medullary and differentiated thyroid cancer, thyroid nodules, and autoimmune thyroid diseases.

Authors:  Cléber P Camacho; Susan C Lindsey; Teresa S Kasamatsu; Alberto L Machado; João Roberto M Martins; Rosa Paula M Biscolla; Magnus R Dias da Silva; José Gilberto H Vieira; Rui M B Maciel
Journal:  Eur Thyroid J       Date:  2014-06-18

4.  [The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors].

Authors:  Joanna Kłubo-Gwieździńska; Roman Junik
Journal:  Endokrynol Pol       Date:  2008 Mar-Apr       Impact factor: 1.582

Review 5.  Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.

Authors:  Chae Moon Hong; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2018-05-02

6.  The Effect of Diagnostic Absorbed Doses from 131I on Human Thyrocytes in Vitro.

Authors:  Zbigniew Adamczewski; Mariusz Stasiołek; Bolesław Karwowski; Marek Dedecjus; Daria Orszulak-Michalak; Anna Merecz; Przemysław W Śliwka; Bartosz Puła; Andrzej Lewiński
Journal:  Int J Mol Sci       Date:  2015-06-29       Impact factor: 5.923

7.  Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I(131)Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy.

Authors:  Syed Zubair Hussain; Maseeh Uz Zaman; Sarwar Malik; Nanik Ram; Ali Asghar; Unaib Rabbani; Nida Aftab; Najmul Islam
Journal:  J Thyroid Res       Date:  2014-04-09

8.  Nuclear Molecular and Theranostic Imaging for Differentiated Thyroid Cancer.

Authors:  Arif Sheikh; Berna Polack; Yvette Rodriguez; Russ Kuker
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-09

9.  Development of an athyroid mouse model using 131I ablation after preparation with a low-iodine diet.

Authors:  Ji Min Oh; Ho Won Lee; Senthilkumar Kalimuthu; Prakash Gangadaran; Se Hwan Baek; Man-Hoon Han; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

Review 10.  Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review.

Authors:  Mojtaba Ansari; Mostafa Rezaei Tavirani
Journal:  Iran J Pharm Res       Date:  2022-05-14       Impact factor: 1.962

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.